{
  "Johnson & Johnson": {
    "2024": {
      "FORM": "8-K",
      "CATEGORIES": {
        "Section 2 - Financial Information": {
          "ITEMS": {
            "Item 2.02 - Results of Operations and Financial Condition": {
              "content": "On May 1, 2024, Johnson & Johnson issued the attached earnings schedules for the first quarter ended March 31, 2024. These schedules have been amended to reflect the information referenced in Item 7.01.",
              "subsections": {}
            }
          }
        },
        "Section 7 - Regulation FD": {
          "ITEMS": {
            "Item 7.01 - Regulation FD Disclosure": {
              "content": "On May 1, 2024, the Company announced a proposed Plan of Reorganization (the “Proposed Plan”) for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.4 billion, discounted at a rate of 4.4%).",
              "subsections": {
                "accounting_impact": "To account for these settlements and the contemplated comprehensive resolution through the Proposed Plan, the Company recorded an incremental charge of approximately $2.7 billion, for a total reserve as of the first fiscal quarter 2024 at a present value of approximately $11 billion (nominal value of approximately $13.7 billion).",
                "earnings_restatement": "The Proposed Plan is a recognized subsequent event and previously reported GAAP net earnings for the fiscal first quarter ended March 31, 2024 is reduced from $5.4 billion to $3.3 billion. Previously reported earnings per share (EPS) for the fiscal first quarter ended March 31, 2024 is reduced from $2.20 to $1.34. There is no impact to previously reported Adjusted Earnings, Adjusted EPS and Adjusted Operational EPS for the fiscal first quarter ended March 31, 2024.",
                "related_exhibit": "The press release further discussing this announcement is attached below as Exhibit 99.2."
              }
            }
          }
        },
        "Section 9 - Financial Statements and Exhibits": {
          "ITEMS": {
            "Item 9.01 - Financial Statements and Exhibits": {
              "content": "(d) Exhibits.",
              "subsections": {
                "exhibit_99.1": "Condensed Consolidated Statement of Earnings and Non-GAAP Reconciliations for the fiscal first quarter",
                "exhibit_99.2": "Press Release dated May 1, 2024.",
                "exhibit_104": "The cover page from this Current Report on Form 8-K, formatted in Inline XBRL."
              }
            }
          }
        }
      }
    }
  }
}